What Is Ipamorelin and Where Did It Come From?
Ipamorelin is a synthetic pentapeptide developed by the pharmaceutical company Novo Nordisk during the late 1990s and early 2000s. It belongs to a class of compounds known as growth hormone-releasing peptides, or GHRPs for short. But unlike many of its counterparts in this family, ipamorelin carved out a unique reputation for its selectivity.
The peptide was originally researched for gastrointestinal applications before scientists noticed its potent effects on growth hormone secretion. What made ipamorelin stand out in early research was its ability to stimulate GH release while producing significantly less activation of the adrenal axis compared to non-selective alternatives. This selectivity caught the attention of researchers working in performance optimization and anti-aging medicine, where growth hormone plays a central role in tissue repair, metabolism, and overall vitality.
Chemically, ipamorelin is a pentapeptide with a molecular weight of approximately 582.7 g/mol. It functions as a selective agonist at the ghrelin receptor, specifically the GHSR-1a subtype. This targeted binding is what gives ipamorelin its distinctive profile among other peptides in the same family. Researchers studying growth hormone secretagogues often describe it as the most selective member of the GHRP class, largely because of how precisely it interacts with its target receptor without broadly activating unrelated pathways.
